News and Announcements
OncoSil Medical’s CEO Presents at ASX CEO Session
- Published November 17, 2015 4:37PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
17th November 2015, ASX Announcement
Developing implantable radiotherapy medical device
- 30 micron silicon particles contain beta emitting phosphorous (P32)
- Safer and stronger medical radiation treatment than external beam radiation
Successfully developed – preparing for EU commercialisation
- Four pilot clinical studies completed
-2 in primary liver/ hepatcellular carcinoma
-2 in pancreatic cancer - Excellent results to support Conformité Européene (CE) Marketing filings for both primary liver and pancreatic cancer & US FDA IDE submission
- Safety evaluations suggest that OncoSil is well tolerated in patients with unresectable primary liver and pancreatic cancer
- Efficacy data showed that OncoSil induces significant reduction in tumour volume in both liver and pancreas cancer and significantly reduces pain
To view the full presentation, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
